Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 35 member D2 (SLC35D2) is a nucleotide sugar transporter located in the Golgi apparatus that exchanges UDP-N-acetylglucosamine (UDP-GlcNAc) and UDP-glucose (UDP-Glc) from the cytosol into the Golgi lumen in exchange for UMP. This process provides essential nucleotide sugars for glycosyltransferases, enabling the biosynthesis of glycosaminoglycans and other glycoconjugates. SLC35D2 is part of the SLC35 nucleotide sugar transporter family, showing approximately 50% identity with SLC35D1 and is critical for normal glycosylation processes in humans. Genetic variants in SLC35D2 have been associated with disorders involving defective glycosylation and immune function. No known drugs directly target SLC35D2 as of the current literature, and there are no established clinical biomarkers or mechanisms of action involving pharmacological modulation of this transporter. Dysfunction in SLC35D2 can result in significant congenital disorders and altered immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 35 member D2 (SLC35D2).